-
Mashup Score: 0
“What I’m quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
Eligible patients for the multicenter, nonrandomized, single-arm trial (NCT05249127) will have suspected recurrence of prostate cancer as determined by a rising prostate-specific antigen following definitive therapy.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
COBRA study launches exploring Cu-64 SAR-bisPSMA in biochemically recurrent prostate cancer https://t.co/5Sy4PsPtoh #urology #urologist #pcsm #prostatecancer #urooncology
-
-
Mashup Score: 1
At the 2022 NY GU Cancers Symposium, Jean Hoffman-Censits, MD, discussed the latest developments in the neoadjuvant and adjuvant setting for patients with bladder cancer.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Ongoing advances in the perioperative management of bladder cancer https://t.co/R9SBTueRBV #urology #urologist #bladdercancer #urooncology
-
-
Mashup Score: 0Study shows feasibility of incorporating hereditary cancer risk assessments into community urology practices - 2 year(s) ago
“The traction on this, I think, is really rather remarkable,” says Neal D. Shore, MD, FACS.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Study shows feasibility of incorporating hereditary cancer risk assessments into community urology practices https://t.co/ztWyOtUDaM #urology #urologist #urooncology #genetictesting
-
-
Mashup Score: 1
“The majority of patients were able to stay on the dose of the apalutamide,” says Mario E. Lacouture, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Management of dermatologic adverse events with apalutamide in prostate cancer https://t.co/ebasiPC9Tl #urology #urologist #pcsm #prostatecancer #urooncology @MSKCancerCenter
-
-
Mashup Score: 0
New data from the ongoing phase 1b/2 trial on combination therapy with batiraxcept plus cabozantinib (Cabometyx) continue to demonstrate favorable outcomes in patients with clear cell renal cell carcinoma (ccRCC).1According to Aravive, the developer of the GAS6-AXL pathway inhibitor batiraxcept, the 6-month progression-free survival (PFS) rate and the best overall response rate (ORR) of the…
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Efficacy of batiraxcept/cabozantinib combo in clear cell RCC: Updated results https://t.co/2lFd2wssX1 #urology #urologist #kcsm #urooncology #kidneycancer
-
-
Mashup Score: 0What will be the next GOAT for bladder cancer? - 2 year(s) ago
“The future is bright for immunotherapy in bladder cancer,” writes Michael S. Cookson, MD, MMHC.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
What will be the next GOAT for bladder cancer? https://t.co/R2raWbkKGm #urology #urologist #bladdercancer #guoncology #urooncology
-
-
Mashup Score: 0Nivolumab/Cabozantinib combo continues to show HRQOL benefit in renal cell carcinoma - 2 year(s) ago
Long-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Nivolumab/Cabozantinib combo continues to show HRQOL benefit in renal cell carcinoma https://t.co/ZGmUd4rCMS #urology #urologist #kcsm #kidneycancer #urooncology
-
-
Mashup Score: 0
Efficacy and safety data from the final analysis of the retrospective CaboCHECK trial support the use of cabozantinib in patients with advanced or metastatic renal cell carcinoma after progression on immunotherapy.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Study supports post-immunotherapy cabozantinib for metastatic kidney cancer https://t.co/8TfngTRepf #urology #urologist #kcsm #kidneycancer #urooncology
-
-
Mashup Score: 3No OS benefit at 1-year mark with upfront avelumab in cisplatin-ineligible urothelial cancer - 2 year(s) ago
Despite missing the primary end point, avelumab did demonstrate notable clinical activity and a favorable safety profile in the phase 2 ARIES trial.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
No OS benefit at 1-year mark with upfront avelumab in cisplatin-ineligible urothelial cancer https://t.co/yLK2f8lT1S #urology #urologist #urothelialcancer #bladdercancer #urooncology
-
Dr. Tagawa discusses the evolving potential of radiopharmaceuticals in prostate cancer https://t.co/0jXQQ4A4gf #urology #urologist #radiology #radiologist #urooncology #prostate